Table 3.
Comparison of Primary Cardiovascular Disease Prevention Therapies in Women1
| Outcome | HRT2 | Lipid-Lowering | Aspirin | ACE-I |
|---|---|---|---|---|
|
| ||||
| CHD | 0.68 (0.48–0.96) (25) | 0.89 (0.69–1.09) (33) | 1.01 (0.84–1.21) (39) | |
| 0.52 (0.29–0.96) (26) | 0.95 (0.78–1.16) (34) | 0.99 (0.83–1.19) (40) | ||
| 0.79 (0.56–1.13) (36) | 0.91 (0.80–1.03) (40) | |||
| 0.83 (0.64–1.09) (38) | 0.88 (0.53–1.44) (41) | |||
| 0.85 (0.60–1.20) (42) | ||||
| 0.92 (0.78–1.09) (43) | ||||
| All-cause morality | 0.61 (0.39–0.95) (24) | 0.95 (0.62–1.46) (33) | 0.94 (0.74–1.19) (39) | 1.00 (0.83–1.21) (47) |
| 0.73 (0.52–0.96) (29) | 0.96 (0.81–1.13) (34) | 1.09 (0.91–1.30) (44–46) | 0.92 (0.81–1.04) (48)3 | |
| 0.70 (0.52–0.95) (26) | 0.91 (0.76–1.08) (36) | |||
| 0.93 (0.80–1.08) (38) | ||||
1
Risk ratio (95% confidence interval)
2
Women <60 years old and/or <10 years-since-menopause at time of randomization
3
Mortality from heart failure
HRT = hormone replacement therapy; ACE-I = angiotensin converting enzyme inhibitor; CHD = coronary heart disease